Literature DB >> 35783664

A Comprehensive Review of Celecoxib Oral Solution for the Acute Treatment of Migraine.

Nazir Noor1, Courtney LaChute2, Mathew Root2, Jasmine Rogers2, Madeleine Richard2, Giustino Varrassi3, Ivan Urits4, Omar Viswanath5, Nazih Khater6, Alan D Kaye2.   

Abstract

A migraine is a clinical diagnosis with a presentation of one or more severe unilateral or bilateral headache(s) often preceded by an aura and typically accompanied by nausea, vomiting, photophobia, and/or phonophobia. This neurological disease is often debilitating and greatly affects the quality of life of those it inflicts. In fact, a recent study conducted by the Global Burden of Disease and published in The Lancet Neurology revealed that migraines ranked second to only back pain as the most disabling disease. Triggers for migraines have ranged from female sex, low socioeconomic status, and diet to loud noises, sleep hygiene, and stress. Along with its clinical presentation, laboratory tests and imaging help rule out other potential causes of the headache and lead to a diagnosis of migraine. Migraines are typically divided into three phases: prodromal, headache, and postdrome. The pathophysiology of each phase remains under investigation, with differing theories regarding their pathways. Existing therapies are abortive therapies for acute migraines or preventative therapies. Abortive therapy consists of NSAIDs and triptans. Preventative therapies include tricyclic antidepressants, calcium channel blockers, beta-blockers, and anticonvulsants. In this review, we focus on the role of NSAIDs and the COX-2 inhibitor, celecoxib oral solution, for the abortive treatment of acute migraines.

Entities:  

Keywords:  celecoxib; headache; migraine; selective COX-2 inhibitor

Year:  2022        PMID: 35783664      PMCID: PMC9242839          DOI: 10.52965/001c.34265

Source DB:  PubMed          Journal:  Health Psychol Res        ISSN: 2420-8124


  60 in total

1.  Clinical efficacy evaluation and prevention of adverse reactions in a randomized trial of a combination of three drugs in the treatment of cancerous pudendal neuralgia.

Authors:  Junjie Hou; Yifan Lin; Yanqiu Fang; Xiaonan Li; Xiao-Nan Li; Ying Yang; Ning Liu; Xianzhuo Jiang; Yingying Yu; Ying Zhou; Xuguang Mi; Zhiqiang Ni; Xiaodan Lu; Ning-Yi Jin
Journal:  Ann Palliat Med       Date:  2021-05-06

2.  Prevalence and burden of migraine in the United States: data from the American Migraine Study II.

Authors:  R B Lipton; W F Stewart; S Diamond; M L Diamond; M Reed
Journal:  Headache       Date:  2001 Jul-Aug       Impact factor: 5.887

3.  Efficacy of celecoxib as preemptive analgesia for patients undergoing laparoscopic inguinal hernia repair: a randomized trial.

Authors:  Takuya Saito; Shigeyoshi Iwamoto; Kenta Murotani; Atsushi Hashimoto; Shintaro Kurahashi; Yasuyuki Fukami; Shunichiro Komatsu; Kenitiro Kaneko; Hideyuki Mishima; Tsuyoshi Sano
Journal:  Surg Today       Date:  2021-01-03       Impact factor: 2.549

4.  Intracerebral hemorrhage following possible interaction between celecoxib and clopidogrel.

Authors:  A A Fisher; D G Le Couteur
Journal:  Ann Pharmacother       Date:  2001-12       Impact factor: 3.154

5.  Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial.

Authors:  P T Leese; R C Hubbard; A Karim; P C Isakson; S S Yu; G S Geis
Journal:  J Clin Pharmacol       Date:  2000-02       Impact factor: 3.126

Review 6.  Sex differences in the epidemiology, clinical features, and pathophysiology of migraine.

Authors:  Kjersti Grøtta Vetvik; E Anne MacGregor
Journal:  Lancet Neurol       Date:  2016-11-09       Impact factor: 44.182

7.  Discovery of cyclooxygenase-2 inhibitors from Kadsura coccinea by affinity ultrafiltration mass spectrometry and the anti-inflammatory activity.

Authors:  Xiang-Yun Zhang; Zi-Jiao Wei; Wei-Li Qiao; Xiao-Min Sun; Zhi-Ling Jin; Wen Gong; Bei-Xi Jia
Journal:  Fitoterapia       Date:  2021-02-28       Impact factor: 2.882

Review 8.  A Phase-by-Phase Review of Migraine Pathophysiology.

Authors:  David W Dodick
Journal:  Headache       Date:  2018-05       Impact factor: 5.887

9.  Photo-, osmo- and phonophobia in the premonitory phase of migraine: mistaking symptoms for triggers?

Authors:  Laura H Schulte; Tim P Jürgens; Arne May
Journal:  J Headache Pain       Date:  2015-02-15       Impact factor: 7.277

10.  The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results.

Authors:  Aubrey Manack Adams; Daniel Serrano; Dawn C Buse; Michael L Reed; Valerie Marske; Kristina M Fanning; Richard B Lipton
Journal:  Cephalalgia       Date:  2014-10-10       Impact factor: 6.292

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.